English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Terbium has attracted the attention of researchers and physicians due to the existence of four medically interesting radionuclides, potentially useful for SPECT and PET imaging, as well as for α- and β − -radionuclide therapy. The aim of this study was to produce  152 Tb ( T  1/2  = 17.5 h, E β+av  = 1140 keV) and evaluate it in a preclinical setting in order to demonstrate its potential for PET imaging. For this purpose, DOTANOC was used for targeting the somatostatin receptor in AR42J tumor-bearing mice.    Methods   152 Tb was produced by proton-induced spallation of tantalum targets, followed by an online isotope separation process at ISOLDE/CERN. After separation of  152 Tb using cation exchange chromatography, it was directly employed for radiolabeling of DOTANOC. PET/CT scans were performed with AR42J tumor-bearing mice at different time points after injection of  152 Tb-DOTANOC which was applied at variable molar peptide amounts.  177 Lu-DOTANOC was prepared and used in biodistribution and SPECT/CT imaging studies for comparison with the PET results.    Results  After purification,  152 Tb was obtained at activities up to ~600 MBq. Radiolabeling of DOTANOC was achieved at a specific activity of 10 MBq/nmol with a radiochemical purity >98 %. The PET/CT scans of mice allowed visualization of AR42J tumor xenografts and the kidneys, in which the radiopeptide was accumulated. After injection of large peptide amounts, the tumor uptake was reduced as compared to the result after injection of small peptide amounts. PET images of mice, which received  152 Tb-DOTANOC at small peptide amounts, revealed the best tumor-to-kidney ratios. The data obtained with  177 Lu-DOTANOC in biodistribution and SPECT/CT imaging studies confirmed the  152 Tb-based PET results.    Conclusions  Production of 30-fold higher quantities of  152 Tb as compared to the previously performed pilot study was feasible. This allowed, for the first time, labeling of a peptide at a reasonable specific activity and subsequent application for in vivo PET imaging. As a β + -particle-emitting radiolanthanide,  152 Tb would be of distinct value for clinical application, as it may allow exact prediction of the tissue distribution of therapeutic radiolanthanides.    Electronic supplementary material  The online version of this article (doi:10.1186/s13550-016-0189-4) contains supplementary material, which is available to authorized users.

Preclinical in vivo application of 152Tb-DOTANOC: a radiolanthanide for PET imaging